Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 8/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.35 |
| ▸ | GCKR | Q14397 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | USP8 | P40818 | 1/20 | 0.35 |
| ▸ | POLQ | O75417 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25734379 | 0.88 | KDM4E (0.51) | FABP4ACLYKDM4EALDH1A1LMNA | |
| SCHEMBL25734719 | 0.88 | FABP4 (0.40) | FABP4ACLYKDM4EALDH1A1LMNA | |
| SCHEMBL25737555 | 0.87 | ACLY (0.42) | FABP4ACLYKDM4EKDM1AALDH1A1 | |
| SCHEMBL25737584 | 0.83 | FABP4 (0.40) | FABP4ACLYKDM4EKDM1AALDH1A1 | |
| SCHEMBL25734681 | 0.83 | ACLY (0.39) | FABP4ACLYKDM4EKDM1ALMNA | |
| SCHEMBL25737564 | 0.83 | ACLY (0.39) | FABP4ACLYKDM4EKDM1ALMNA | |
| SCHEMBL25737566 | 0.83 | ACLY (0.39) | FABP4ACLYKDM4EKDM1ALMNA | |
| SCHEMBL25073564 | 0.82 | FABP4 (0.43) | FABP4ACLYKDM4EKMT2A | |
| SCHEMBL25734682 | 0.82 | FABP4 (0.39) | FABP4ACLYKDM4EALDH1A1KMT2A | |
| SCHEMBL25737607 | 0.82 | FABP4 (0.40) | FABP4ACLYKDM4EKDM1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B1, HSD17B13, HSD17B3 | FABP4 781/4885ACLY 421/4885KDM4E 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.